Free Trial

Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below 50 Day Moving Average - What's Next?

Cipher Pharmaceuticals logo with Medical background

Key Points

  • Cipher Pharmaceuticals (TSE:CPH) shares fell below their 50-day moving average of C$15.30, reaching a low of C$14.41 during trading.
  • The company's stock price is down 2.1%, with a current trading price of C$14.57 and a market capitalization of C$369.99 million.
  • Cipher Pharmaceuticals operates in both Canada and the United States, specializing in dermatology and acute care products.
  • MarketBeat previews top five stocks to own in November.

Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR's share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$15.30 and traded as low as C$14.41. Cipher Pharmaceuticals shares last traded at C$14.57, with a volume of 33,928 shares changing hands.

Cipher Pharmaceuticals Stock Down 2.1%

The company has a 50-day simple moving average of C$15.30 and a 200 day simple moving average of C$13.55. The company has a market cap of C$369.99 million, a P/E ratio of 31.67 and a beta of 0.77. The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cipher Pharmaceuticals Right Now?

Before you consider Cipher Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.

While Cipher Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.